Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Shionogi & Co ( (JP:4507) ).
Shionogi & Co., Ltd. announced corrections to its Consolidated Financial Results for the second quarter of fiscal year 2025. The corrections involve numerical data related to the number of shares issued and treasury stock, as well as the pro forma information on revenue and profit from a business combination. These adjustments may impact stakeholders’ understanding of the company’s financial performance and projections.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen3119.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a pharmaceutical company primarily engaged in the research, development, and marketing of pharmaceutical products. The company focuses on creating innovative medicines, with a strong presence in the Japanese market and a growing international footprint.
Average Trading Volume: 2,575,690
Technical Sentiment Signal: Buy
Current Market Cap: Yen2427.5B
Find detailed analytics on 4507 stock on TipRanks’ Stock Analysis page.